JP2019515035A5 - - Google Patents

Download PDF

Info

Publication number
JP2019515035A5
JP2019515035A5 JP2019508162A JP2019508162A JP2019515035A5 JP 2019515035 A5 JP2019515035 A5 JP 2019515035A5 JP 2019508162 A JP2019508162 A JP 2019508162A JP 2019508162 A JP2019508162 A JP 2019508162A JP 2019515035 A5 JP2019515035 A5 JP 2019515035A5
Authority
JP
Japan
Prior art keywords
cancer
snp
subject
kras
single nucleotide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019508162A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019515035A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/029938 external-priority patent/WO2017189906A1/en
Publication of JP2019515035A publication Critical patent/JP2019515035A/ja
Publication of JP2019515035A5 publication Critical patent/JP2019515035A5/ja
Priority to JP2022163987A priority Critical patent/JP2022179694A/ja
Pending legal-status Critical Current

Links

JP2019508162A 2016-04-27 2017-04-27 Krasバリアントがん患者の免疫ベースの処置 Pending JP2019515035A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022163987A JP2022179694A (ja) 2016-04-27 2022-10-12 Krasバリアントがん患者の免疫ベースの処置

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662328548P 2016-04-27 2016-04-27
US62/328,548 2016-04-27
PCT/US2017/029938 WO2017189906A1 (en) 2016-04-27 2017-04-27 Immune-based treatment of kras-variant cancer patients

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022163987A Division JP2022179694A (ja) 2016-04-27 2022-10-12 Krasバリアントがん患者の免疫ベースの処置

Publications (2)

Publication Number Publication Date
JP2019515035A JP2019515035A (ja) 2019-06-06
JP2019515035A5 true JP2019515035A5 (enExample) 2020-06-11

Family

ID=59215945

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019508162A Pending JP2019515035A (ja) 2016-04-27 2017-04-27 Krasバリアントがん患者の免疫ベースの処置
JP2022163987A Pending JP2022179694A (ja) 2016-04-27 2022-10-12 Krasバリアントがん患者の免疫ベースの処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022163987A Pending JP2022179694A (ja) 2016-04-27 2022-10-12 Krasバリアントがん患者の免疫ベースの処置

Country Status (5)

Country Link
US (1) US20200325234A1 (enExample)
EP (1) EP3449015A1 (enExample)
JP (2) JP2019515035A (enExample)
CN (1) CN109790581A (enExample)
WO (1) WO2017189906A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018283314B2 (en) 2017-06-15 2025-05-29 Miradx Biomarkers for predicting tumor response to and toxicity of immunotherapy
TW202003582A (zh) * 2018-03-13 2020-01-16 法商天賜製藥公司 頭頸癌之治療
CA3142404A1 (en) * 2019-06-07 2020-12-10 Emory University Kras g12v mutant binds to jak1, inhibitors, pharmaceutical compositions, and methods related thereto

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4988617A (en) 1988-03-25 1991-01-29 California Institute Of Technology Method of detecting a nucleotide change in nucleic acids
WO1989010414A1 (en) 1988-04-28 1989-11-02 Robert Bruce Wallace AMPLIFIED SEQUENCE POLYMORPHISMS (ASPs)
US4988167A (en) 1988-08-10 1991-01-29 Fergason James L Light blocking and vision restoration apparatus with glint control
US5118801A (en) 1988-09-30 1992-06-02 The Public Health Research Institute Nucleic acid process containing improved molecular switch
IE66572B1 (en) 1989-02-13 1996-01-24 Geneco Pty Ltd Detection of a nucleic acid sequence or a change therein
FR2650840B1 (fr) 1989-08-11 1991-11-29 Bertin & Cie Procede rapide de detection et/ou d'identification d'une seule base sur une sequence d'acide nucleique, et ses applications
US5302509A (en) 1989-08-14 1994-04-12 Beckman Instruments, Inc. Method for sequencing polynucleotides
US5494810A (en) 1990-05-03 1996-02-27 Cornell Research Foundation, Inc. Thermostable ligase-mediated DNA amplifications system for the detection of genetic disease
US5210015A (en) 1990-08-06 1993-05-11 Hoffman-La Roche Inc. Homogeneous assay system using the nuclease activity of a nucleic acid polymerase
US6004744A (en) 1991-03-05 1999-12-21 Molecular Tool, Inc. Method for determining nucleotide identity through extension of immobilized primer
ATE198358T1 (de) 1992-04-27 2001-01-15 Dartmouth College Detektion von gensequenzen in biologischen flüssigkeiten
US5547835A (en) 1993-01-07 1996-08-20 Sequenom, Inc. DNA sequencing by mass spectrometry
US5605798A (en) 1993-01-07 1997-02-25 Sequenom, Inc. DNA diagnostic based on mass spectrometry
US5498531A (en) 1993-09-10 1996-03-12 President And Fellows Of Harvard College Intron-mediated recombinant techniques and reagents
US5538848A (en) 1994-11-16 1996-07-23 Applied Biosystems Division, Perkin-Elmer Corp. Method for detecting nucleic acid amplification using self-quenching fluorescence probe
IL108159A (en) 1993-12-23 1998-02-08 Orgenics Ltd Apparatus for separation, concentration and detection of target molecules in liquid sample
EP0754240B1 (en) 1994-02-07 2003-08-20 Beckman Coulter, Inc. Ligase/polymerase-mediated genetic bit analysis of single nucleotide polymorphisms and its use in genetic analysis
IL124967A (en) 1995-12-18 2000-07-26 Univ Washington Method for nucleic acid analysis using fluorescence resonance energy transfer
CA2244891C (en) 1996-02-09 2008-12-30 Cornell Research Foundation, Inc. Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
JP4468488B2 (ja) 1996-05-29 2010-05-26 コーネル・リサーチ・ファンデーション・インコーポレイテッド 組み合せたリガーゼ検出およびポリメラーゼ連鎖反応を用いる核酸配列相違の検出
US5866336A (en) 1996-07-16 1999-02-02 Oncor, Inc. Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6117635A (en) 1996-07-16 2000-09-12 Intergen Company Nucleic acid amplification oligonucleotides with molecular energy transfer labels and methods based thereon
US6506594B1 (en) 1999-03-19 2003-01-14 Cornell Res Foundation Inc Detection of nucleic acid sequence differences using the ligase detection reaction with addressable arrays
CA2676244C (en) * 2007-01-25 2017-01-17 Kwok-Kin Wong Use of anti-egfr antibodies in treatment of egfr mutant mediated disease
AU2008260029B2 (en) 2007-05-31 2015-02-12 Yale University A genetic lesion associated with cancer
US20140065615A1 (en) * 2011-03-21 2014-03-06 Yale University The KRAS Variant and Tumor Biology
EA026924B1 (ru) * 2011-08-01 2017-05-31 Дженентек, Инк. Способы лечения рака с использованием антагонистов, связывающихся с осью pd-1, и ингибиторов mek
CN103547683A (zh) * 2012-03-22 2014-01-29 耶鲁大学 Kras突变和肿瘤生物学
CA2899577C (en) * 2013-04-03 2023-10-17 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2014193937A1 (en) * 2013-05-31 2014-12-04 Yale University The kras variant and response to cancer therapy

Similar Documents

Publication Publication Date Title
Luo et al. DNA methyltransferase inhibition upregulates MHC-I to potentiate cytotoxic T lymphocyte responses in breast cancer
Botticelli et al. The sexist behaviour of immune checkpoint inhibitors in cancer therapy?
Concha-Benavente et al. Identification of the cell-intrinsic and-extrinsic pathways downstream of EGFR and IFNγ that induce PD-L1 expression in head and neck cancer
Papadatos-Pastos et al. Phase 1, dose-escalation study of guadecitabine (SGI-110) in combination with pembrolizumab in patients with solid tumors
JP7564122B2 (ja) 光免疫療法のための方法および関連バイオマーカー
US20240344138A1 (en) Targeted therapies in cancer
JP2020535230A (ja) 腫瘍変異負荷
CN107923918A (zh) 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法
US20220175787A1 (en) Patient selection for enhancement of anti-tumor immunity in cancer patients
US12486334B2 (en) Chemically controlled monoclonal antibody target engagement
Church et al. Transcriptional and functional analyses of neoantigen-specific CD4 T cells during a profound response to anti-PD-L1 in metastatic Merkel cell carcinoma
JP2022519649A (ja) がんの診断および治療方法
WO2017205213A1 (en) Combination therapy of abemaciclib and immune checkpoint modulators for use in the treatment of cancer
JP2019515035A5 (enExample)
Wang et al. CD74 is associated with inflamed tumor immune microenvironment and predicts responsiveness to PD-1/CTLA-4 bispecific antibody in patients with solid tumors
Magyari et al. Gender effects on treatment response to interferon‐beta in multiple sclerosis
Someya et al. Combined chemoradiotherapy and programmed cell death‐ligand 1 blockade leads to changes in the circulating T‐cell receptor repertoire of patients with non‐small‐cell lung cancer
EP3612639A1 (en) Biomarker for small cell lung cancer therapy
EP3313431B1 (en) Method for inducing early t memory response with short peptides anti-tumor vaccine
Xu et al. Trastuzumab, in combination with carboplatin and docetaxel, does not prolong the QT interval of patients with HER2-positive metastatic or locally advanced inoperable solid tumors: results from a phase Ib study
Palermo et al. Antigen-specificity and DTIC before peptide-vaccination differently shape immune-checkpoint expression pattern, anti-tumor functionality and TCR repertoire in melanoma patients
Malecki et al. Novel paradigm for immunotherapy of ovarian cancer by engaging prophylactic immunity against hepatitis B virus
Dey et al. Revolutionizing Cancer Therapy: A Comprehensive Review of Immune Checkpoint Inhibitors
US20260048124A1 (en) Methods for treating brain cancer
Kang et al. Selinexor-based treatments are associated with increased expression of T-cell activation markers in multiple myeloma